Explore funding opportunities dedicated to driving healthcare innovation. Whether you're developing groundbreaking solutions or leading collaborative research projects, our funding directory highlights valuable support to help bring your ideas to life.
The list below provides an overview of current funding opportunities and is updated regularly. Please note, this is not an exhaustive directory and only highlights a selection of available calls.
Our funding team has access to a comprehensive global database of funding calls and initiatives. If you're seeking a more extensive and tailored search to find the right opportunities for your innovation, we’re here to help.
Contact us at fundingsupport@lshubwales.com for guidance, bid review and editing, and help finding the perfect opportunity for your project. Last updated: August 2025
The Leukemia & Lymphoma Society funds leading-edge research for every type of blood cancer, including leukaemia, lymphoma, myeloma, and other rare types of blood cancers. The Discovery Grant Program supports cutting edge, discovery-oriented research focused on understanding the properties and vulnerabilities of blood cancers to advance treatment options. The programme encourages established academic investigators to explore blood cancer biology and fund proof-of-concept studies that may lead to entirely novel treatment approaches.
CWR has launched a request for proposals in order to fund proof of concept, Phase I or Phase IIA clinical trials to validate artificial intelligence (AI)-driven repurposing opportunities in any unsolved disease, where the therapies supported by AI models are already approved. Eligible clinical repurposing trials must include AI-generated data as part of the preclinical support for the trial. Supporting data from any type of AI model is accepted for this call, including models that are developed/owned/controlled by non-profit/academic/government institutions or for profit companies, as well as open-use models or models only accessible via collaboration.
HIS offers research grants to support research projects in the field of healthcare-associated infections (HCAIs) and infection prevention and control in the UK or Ireland. The thematic focus is on translational research.
Studentships to support PhD candidates at universities in South West England and South Wales conducting research of relevance to Alzheimer's and other forms of dementia. Applications from areas related to dementia are also welcome.
This award aims to accelerate and drive forward the development of novel drugs for the treatment of Parkinson's. The initiative should provide researchers with the opportunity to generate essential data and help bridge the gaps needed to get their projects/compounds ready to enter full scale drug discovery with an industry partner.
Proposals focusing on optimising the dose of cancer therapies, and that could demonstrate patient benefit through a reduction in side effects or burden of treatment, while maintaining clinical effectiveness.
Starter Grants for Clinical Lecturers provide up to £30,000 over 1–2 years to support early-stage research and strengthen future fellowship applications. An optional £2,500 is available for public and patient involvement. Aimed at bridging the funding gap in Clinical Lecturer posts.
The Neurosciences and Mental Health Board (NMHB) seeks to advance understanding of the nervous system’s physiology and behaviour across the lifespan, in both health and disease, to improve treatment and prevention of brain disorders. Our research focuses on the connections between the nervous system, brain, mental health, and physical health, as well as how life events influence lifelong neurological and mental wellbeing.
The Sarcoma UK grants programme funds scientific and medical research to investigate the mechanisms of all forms of bone and soft tissue cancers and develop more effective diagnostics and treatments. Its Research Strategy for 2021-2026 aims to ensure everyone affected by sarcoma receives the best treatment, care, information and support available and focuses on researching causes, diagnostics and treatment to improve quality of life, balanced across multiple sarcoma subtypes.
Funding available for projects, including clinical trials, pump priming projects, training and audits, aiming to raise the standards of breast care and breast surgery with clear value to the NHS.
The Global Grants for Gut Health is a competitive programme for investigator-initiated research into the human gut microbiota, supported by Yakult and Nature Portfolio. The programme will fund research that develops new insights, data and methodologies with the ultimate goal of advancing the understanding of the impact of the gut microbiota on human health.
Grant funding over a maximum of five years to support researchers, clinical academics and allied health professionals in the UK conducting research that seeks to better understand and improve the quality of life of people living with cancer, or those who have survived cancer.
The Medical Research Foundation is awarding £3 million to research improving life quality for cancer survivors. Focus areas include long-term physical, psychological, and social effects, treatment side effects, risks such as secondary cancers, and mental health. Projects should show clear impact, involve lived experience, and avoid cancer biology or end-of-life care alone.
The GOSH Charity National Paediatric Cancer Clinical Trial Fund is a new funding initiative that will support early phase clinical trials to advance the development of therapeutics for hard to treat paediatric cancers with unmet need. Funding is available for, early phase clinical trials and translational work packages.
RAD's Ignition Fund provides seed funding for exceptional scientists specialising in dementia to support unexpected breakthroughs in their research. The awards are designed to enable scientists to rapidly exploit an opportunity and avoid promising ideas with high potential from being shelved.
The fund seeks to support innovative research that will facilitate a 'stage shift' towards dementia prevention, improved diagnosis, treatment and understanding of the fundamental science of the disease. Applicants do not need any preliminary data in order to apply, but smart and novel new ideas are particularly welcome.
A funding model supported by the Vanguard Initiative, which is a collaborative programme supporting industrial modernisation and innovation through industry-led and cross-regional cooperation.
Fellowships are available for European and Japanese researchers from any discipline to carry out a research visit in either Japan or Europe, respectively.
The Royal Society Faraday Discovery Fellowships offer up to £8 million over 10 years to support mid-career research leaders in science, engineering, or mathematics. Aimed at building world-class UK teams, the fellowships fund salaries, research, and staff. Projects must pursue ambitious, curiosity-driven research with transformative potential, across any discipline.
The Health and Social Care Delivery Research (HSDR) Programme seeks to fund high-quality, well-designed research that addresses the needs of NHS and social care leaders. Projects will be conducted by efficient and capable research teams. This is a two-stage, researcher-led funding opportunity. Applicants submit an outline application first; invited candidates then complete a full application at stage two.
What is the feasibility, acceptability, effectiveness, and cost-effectiveness of newborn screening for spinal muscular atrophy (SMA)? An appropriately designed study to allow the evaluation of the addition of SMA screening to the newborn blood spot screening programme.
What is the clinical and cost-effectiveness of screening for asymptomatic bacteriuria (ASB) in pregnancy? A retrospective study assessing the impact of early pregnancy ASB screening. Applicants should include an internal pilot to confirm data collection feasibility and ensure study completion.
The CRUK research funding programme awards a wide range of fellowships and grants to support researchers, across all career stages, conducting clinical, pre-clinical, discovery and translational research to advance the detection, diagnosis, treatment, and potential cure, of all forms of cancer.
Funding for investigator-led research proposals that meet the remit and mission of the BBSRC, including research projects, new facilities or infrastructure provision, pilot projects, proof of concept studies, equipment purchase and research networks.
The Professor Michael Nicholson Awards programme, funded by Kidney Research UK and the Stoneygate Trust, supports UK-based researchers in advancing kidney transplant science. Aiming to improve transplant longevity, increase kidney availability, and develop machine perfusion techniques, the programme fosters innovation and leadership in the field. Now in its third year, it offers research project grants, start-up grants for new hypotheses, senior non-clinical fellowships, transplant surgeon PhD fellowships, and PhD studentships focused on kidney transplantation.
The ZOLL Foundation is a US-based 501(c)(3) non-profit organisation that was established in 2013 by the ZOLL Medical Corporation. The Foundation provides seed grants for young researchers around the world to support medical research that saves lives. Its scope encompasses a wide range of areas including, but not limited to, emergency medicine, critical care, trauma, cardiovascular health, pulmonary health, neuroscience, and translational research focused on applying discoveries to enhance training and delivery in clinical practice.
The BAPRAS Pump Priming Funds offer up to £20,000 to support UK-based plastic surgeons and trainees in early-stage clinical or laboratory research. Aimed at generating preliminary data or feasibility work, the scheme includes two streams—for clinical trials and lab consumables—and prioritises early-career researchers and new, unstarted projects.
The Anticancer Fund is requesting proposals for projects involving secondary data analysis of data from clinical cancer trials to address new research questions that are beyond the original study objectives. Proposals should focus on research questions aligned with the Anticancer Fund's overall mission: to innovate with existing therapeutic tools to improve survival outcomes.
This scheme offers funding to early-career researchers from any field who are prepared to establish their research identity. Through pioneering projects, they will contribute new insights into human life, health, and wellbeing. By the end of the award period, recipients will be equipped to lead their own independent research programmes.
This scheme provides funding for early-career researchers from any discipline who are ready to develop their research identity. Through innovative projects, they will deliver shifts in understanding related to human life, health and wellbeing. By the end of the award, they will be ready to lead their own independent research programme.
The MRC offers experimental medicine grants for academically-led human intervention studies addressing key gaps in disease understanding. Projects aim to generate mechanistic insights to enable new therapies or diagnostics. All disease areas qualify if the intervention is safe and hypothesis-driven. Applications must show clinical value, strong rationale, and clear milestones.
The EPSRC supports health technology researchers through placements in diverse environments to build skills and collaborations. Funding covers pilot projects, cross-disciplinary research, and skills development focused on improving health, early diagnosis, and new interventions. Placements can last up to 36 months, with flexible arrangements across institutions or industry.
Johnson & Johnson Innovation – JLABS is a global network supporting early-stage life sciences startups in MedTech, pharmaceuticals, and healthcare solutions through funding, incubation, expertise, and industry connections across 11 sites. Their QuickFire Challenge crowdsources innovative solutions worldwide. The current challenge, Unlocking Urologic Oncology, seeks next-generation treatments for genitourinary cancers, specifically bladder and prostate cancer. Innovators can apply for funding, mentorship, and support through JLABS’ global incubator network to advance their solutions.
Funding to support investigator-initiated studies and education projects, on molecular profiling in oncology and reproductive health, with the aim of increasing high quality molecular profiling for health care providers serving cancer patients and improving clinical outcomes.
The Pathfinder Challenge funds early-stage research to develop GenAI autonomous agents aiding clinicians in holistic cancer care. Using advanced AI, including geometric deep learning and graph neural networks, these agents aim to enhance diagnosis, reduce errors, and personalise treatment. Projects focus on breast, cervical, ovarian, prostate, lung, brain, stomach, or colorectal cancers.
This funding call aims to improve how brain-related disorders are diagnosed and how patients are grouped for treatment by focusing on the biological causes of symptoms rather than traditional classification systems. It supports using an existing data platform to bring together and analyse different types of patient information using advanced computer techniques like AI. The results will be tested in clinical studies and the data platform will be made available for future research. The call also stresses working closely with people who have experience of these conditions, healthcare workers, regulators, and others to prepare the healthcare system for these changes. It highlights the importance of fairness, including making sure data is representative, reducing bias, and involving all relevant groups.
This funding call is focused on advancing beta-cell replacement therapies for Type 1 Diabetes (T1D) by tackling key challenges such as developing renewable cell sources, standardising manufacturing processes, improving graft survival and immune tolerance, and creating reliable monitoring and AI-based predictive tools. It seeks to establish regulatory-compliant standards, optimise preclinical and clinical development, define patient-centred outcomes using real-world evidence, explore reimbursement models, and integrate these therapies into diabetes care through collaborative European networks and specialised training. The call emphasises sustainability, regulatory engagement, ethical considerations, and collaboration with existing European projects to accelerate the development of safe, effective, and accessible beta-cell treatments.
The Childhood Cancer Therapeutic Catalyst programme accelerates early-stage therapeutic development for childhood and young people’s cancers. It funds target validation, novel drug approaches, platform and assay development, and drug discovery feasibility.
Prostate Cancer UK, a leading charity, funds bold, innovative UK research to improve prostate cancer diagnosis, treatment, and care. Its 10-year strategy prioritises better diagnosis, treatment, and data use. Research Innovation Awards support clinical and fundamental projects (1–5 years), including pilots, encouraging multidisciplinary, international collaboration and cross-disease ideas.
This funding supports translational research developing innovative, commercially viable technologies for arthritis care. It seeks advanced Proof of Concept projects needing validation of technical, market, or commercial potential to attract industry investment. Focus areas include medical devices, diagnostics, cell therapy, regenerative medicine, and novel therapeutics.
Founded in 1971, COST is an intergovernmental framework supporting European scientific cooperation by funding networking activities, not research. COST Actions are four-year interdisciplinary networks open to researchers from academia, SMEs, and public bodies across all science fields. Proposals must involve at least seven member countries and promote inclusivity and interdisciplinarity.
Research and Partnership Hubs for a Healthy Society will establish large, multidisciplinary hubs that harness engineering and physical sciences to build strategic research capacity in healthcare technologies. The aim is to support healthier lives through advances in prevention, early diagnosis, and self-management of health.
The Engineering and Physical Sciences Research Council (EPSRC) is providing funding to establish a large-scale multidisciplinary research hub drawing on expertise across the EPSRC and health research community to support people to live healthier lives and prevent ill health. Proposals should address long term research challenges in the priority area(s) of prevention, early diagnosis and self-management of health.
The Wellcome Mental Health Award: Transforming Early Intervention funds research on scalable interventions for young people with anxiety, depression, or psychosis. It offers a £200,000 Foundation Phase (12 months) to develop proposals, followed by a £5–8 million Impact Phase (up to five years) to implement and evaluate effective, feasible, and sustainable projects.
This Notice of Funding Opportunity (NOFO) supports pilot studies exploring the biological and genetic causes of cancer health disparities. Funding is available for mechanistic research, new models and methods, and secondary data analysis. The NOFO also aims to build a national network of researchers in this field and expand key resources like biospecimens and patient-derived models. Early-stage projects that lay the groundwork for future in-depth studies are encouraged.
Sigma Theta Tau International Honour Society of Nursing - known as Sigma - is an international representative body for nurses and nursing. Its mission is to advance world health and celebrate nursing excellence in scholarship, leadership and service, and to respond to trends and issues in nursing and healthcare. The Sigma/Council for Advancement of Nursing Science (CANS) grant encourages qualified nurses to improve global health through research. Proposals for clinical, educational or historical research, including plans for broadly disseminating the research findings, may be submitted for the grant.
The NIHR Public Health Research Programme invites applications to develop dynamic models assessing public policies on e-cigarette and tobacco use. Research should evaluate effects of pricing, regulation, marketing, and quitting support on different populations and health inequalities. Economic evaluation, stakeholder involvement, and knowledge mobilisation are essential.
This NIHR Public Health Research funding call is seeking a single UK-based research consortium to explore how local climate change adaptation efforts affect health and health inequalities. With up to £2.5 million available over 3–5 years, the funded work will evaluate local government-led interventions (excluding health sector-specific actions) and generate evidence, best-practice recommendations, and real-world solutions. The goal is to support effective, inclusive climate adaptation that addresses the wider determinants of health and reduces health disparities.
The NIHR is funding a multicentre cluster randomised trial (£1,996,829; Jan 2024–May 2027) to evaluate a primary care training and support programme for the secondary prevention of domestic violence and abuse. The study will assess the intervention’s effectiveness and cost-effectiveness, providing robust evidence to inform responses to serious violence.
PHR Call 2025/340 invites a single research consortium to conduct a 3–5 year programme evaluating the impact of local climate change adaptation on health and health inequalities. Backed by NIHR’s focus on climate, health, and sustainability, the research will assess how local and regional government actions to adapt to climate risks affect population health, particularly in vulnerable communities. The programme should generate real-world, scalable solutions and best-practice recommendations to support equitable local adaptation. Multidisciplinary UK-based consortia can apply for up to £2.5 million, with a two-stage application process via NIHR’s online system.
This Funding Opportunity Announcement (FOA) supports discrete, well-defined projects in any area of cancer research using the National Institutes of Health R03 small grant mechanism. The National Institutes of Health R03 small grant mechanism supports discrete, well-defined projects that realistically can be completed in two years and that require limited levels of funding. Examples of the types of projects that the R03 grant mechanism include, but are not limited to, the following: Pilot or feasibility studies.Secondary analysis of existing data.Small, self-contained research projects.Development of research methodology.Development of new research technology.
Friends for an Earlier Breast Cancer Test (Earlier.org) is a US-based non-profit organisation, established in 1995, that is dedicated exclusively to funding research focused on developing innovative methods for the earlier detection of breast cancer. Its mission is to support the creation of a biological test capable of identifying breast cancer at its earliest stages, potentially even before a tumour has formed. Earlier.org provides funding to support pilot projects that explore new techniques for early breast cancer detection. Grants are intended to provide preliminary data that can lead to more substantial peer-reviewed funding.
This Notice of Funding Opportunity (NOFO) invites mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites and contexts in which expectancy effects can be leveraged to improve cancer outcomes. Expectancies are defined in this context as beliefs about future outcomes, including one's response to cancer or cancer treatment. Expectancies can be evoked by social, psychological, environmental and systemic factors. Expectancy effects are the cognitive, behavioural and biological outcomes caused by expectancies. Expectancy effects can be generated by expectancies held by patients, clinicians, family members, caregivers and/or dyadic/social networks.
The Oxford–Harrington Rare Disease Scholar Award supports UK-based researchers advancing rare disease discoveries towards clinical impact. Scholars receive £100,000, tailored drug development expertise, and project support. Offered by the Oxford–Harrington Rare Disease Centre, the award also provides access to further funding while allowing researchers to retain full intellectual property rights.
The NIHR Work and Health Research Awards fund large, cross-disciplinary projects tackling key issues like long-term conditions, disability, sickness absence, COVID-19 impact, workforce mental health, and health inequalities. Aimed at improving employment and health outcomes, proposals should involve cross-sector teams, support implementation in systems like ICSs, and deliver public benefit.
This NIHR funding supports research into community-based interventions to improve veterans’ mental and physical health. It should address challenges of transition, stigma, and access through population-level approaches such as housing, employment, and coordinated care. Robust outcomes, economic evaluation, and stakeholder engagement are essential to inform policy and enhance holistic care.
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) is inviting research projects that implement early phase (Phase 0, I and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of NCI's Division of Cancer Treatment and Diagnosis (DCTD) and Office of HIV and AIDS Malignancies (OHAM). The proposed project must involve at least one clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program, and/or the HIV and AIDS Malignancies Research Programs.
